Could existing cancer drugs tackle rare tumors? new trial aims to find out
NCT ID NCT07440290
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests whether two approved drugs, dabrafenib and trametinib, can treat rare cancers that have a specific genetic change called BRAF V600. These drugs are already used for melanoma and lung cancer, but researchers want to see if they help people with other cancer types. About 30 adults, children, and teenagers with BRAF V600-positive cancers will take the drugs daily. The goal is to see if tumors shrink or stop growing for at least 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dabrafenib and trametinib (oral targeted therapy drugs)
- What this could lead to
- If successful, this could expand access to these drugs for people with rare cancers that have a BRAF V600 mutation, offering a new treatment option where few exist.
- What could go wrong
- This is an early-to-mid stage trial with only 30 participants, so results may not apply broadly. The drugs may not work for all cancer types, and side effects like fever, rash, or heart issues are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Addenbrooke's Hospital
Cambridge, CB2 OQQ, United Kingdom
-
Alder Hey Hospital
Liverpool, L14 5AB, United Kingdom
-
Belfast City Hospital
Belfast, BT9 7AB, United Kingdom
-
Birmingham Children's Hospital
Birmingham, B4 6NH, United Kingdom
-
Bristol Haematology and Oncology Centre
Bristol, BS2 8ED, United Kingdom
-
Bristol Royal Hospital for Children
Bristol, BS2 8BJ, United Kingdom
-
Cardiff Children's Hospital
Cardiff, CF14 4XW, United Kingdom
-
Churchill Hospital
Oxford, OX3 7LE, United Kingdom
-
Clatterbridge Cancer Centre
Metropolitan Borough of Wirral, CH63 4JY, United Kingdom
-
Freeman Hospital
Newcastle, NE7 7DN, United Kingdom
-
Great North Children's Hospital
Newcastle, NE1 4LP, United Kingdom
-
Great Ormond Street Hospital
London, WC1N 3JH, United Kingdom
-
Guy's Hopsital
London, SE1 9RT, United Kingdom
-
John Radcliffe Hospital
Oxford, OX3 9DU, United Kingdom
-
Leicester Royal Infirmary
Leicester, LE1 5WW, United Kingdom
-
Royal Hospital for Children Glasgow
Glasgow, G51 4TF, United Kingdom
-
Royal Manchester Children's Hospital
Manchester, M13 9WL, United Kingdom
-
Sheffield's Children's Hospital
Sheffield, S10 2TH, United Kingdom
-
Southampton General Hospital
Southampton, United Kingdom
-
The Beatson Hospital
Glasgow, G12 OYN, United Kingdom
-
The Christie Hospital
Manchester, M20 4BX, United Kingdom
-
The Royal Marsden Hospital
Sutton, SM2 5PT, United Kingdom
-
University College London Hospital
London, NW1 2BU, United Kingdom
-
University Hospital Birmingham
Birmingham, B15 2TT, United Kingdom
-
Velindre Cancer Centre
Cardiff, CF14 2TL, United Kingdom
-
Western General Hospital
Edinburgh, EH4 2XU, United Kingdom
-
Weston Park Hospital
Sheffield, S10 2SJ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?